Compositions and methods for the treatment of immunodeficiency
The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
1. An immunotherapeutic composition comprising:
A) immune globulin prepared from a pooled plasma composition comprising plasma samples from 500 or more human plasma donors, wherein the pooled plasma composition has a final RSV neutralization titer of at least 1800, and an antibody titer for parainfluenza virus 1 and/or parainfluenza virus 2 that is at least 1.3 times greater than the antibody titer in a control sample, wherein the control sample is a mixture of plasma samples obtained from 500 or more random human plasma donors, wherein less than 50% of the donor plasma samples used for pooling are from donors with a final RSV neutralization titer of at least 1800; and
B) a pharmaceutically acceptable carrier.
2. The immunotherapeutic composition of claim 1 , further comprising: C) an anti-toxin agent.
3. The immunotherapeutic composition of claim 2 , wherein the anti-toxin agent is a mono-specific, bi-specific or multi-specific antibody with specificity toward a bacterial or fungal toxin.
4. The immunotherapeutic composition of claim 3 , wherein the bacterial or fungal toxin is selected from the group consisting of Botulinum neurotoxin, Tetanus toxin, E. coli toxin, Clostridium difficile toxin, Vibrio RTX toxin, Staphylococcal toxins, Cyanobacteria toxin, and mycotoxins.
5. The immunotherapeutic composition of claim 1 , wherein the pooled plasma composition comprises neutralizing antibodies specific for one or more of Corynebacterium diphtheria , measles virus, and polio virus.
6. The immunotherapeutic composition of claim 1 , further comprising a biologically active agent selected from the group consisting of an anti-inflammatory agent, an anti-cancer agent, an anti-microbial agent, an antihistamine, a cytokine, and a chemokine.
7. The immunotherapeutic composition of claim 1 , further comprising an immunotherapeutic agent selected from the group consisting of a recombinant antibody, an antibody fragment, an antibody-like molecule, a monoclonal antibody, an antiviral, an immunotherapeutic protein and an immunotherapeutic small molecule.
8. The immunotherapeutic composition of claim 1 , further comprising an anti-inflammatory agent selected from the group consisting of a recombinant antibody, an antibody fragment, a monoclonal antibody, an anti-inflammatory protein and an anti-inflammatory small molecule.
9. The immunotherapeutic composition of claim 1 , further comprising an antibody titer for coronavirus OC43 and/or coronavirus 229E that is at least 1.3 times greater than the antibody titer in the control sample.
10. The immunotherapeutic composition of claim 1 , further comprising an antibody titer for influenza A virus, influenza B virus, and/or metapneumovirus that is at least 1.3 times greater than the antibody titer in the control sample.
11. The immunotherapeutic composition of claim 1 , wherein 30-45% of the donor plasma samples used for pooling are from donors with a final RSV neutralization titer of at least 1800.
12. A method of providing immunotherapy to a subject comprising administering to the subject a therapeutically effective amount of an immunotherapeutic composition comprising:
A) immune globulin prepared from a pooled plasma composition comprising plasma samples from 500 or more human plasma donors, wherein the pooled plasma composition has a final RSV neutralization titer of at least 1800, and an antibody titer for parainfluenza virus 1 and/or parainfluenza virus 2 that is at least 1.3 times greater than the antibody titer in a control sample, wherein the control sample is a mixture of plasma samples obtained from 500 or more random human plasma donors, wherein less than 50% of the donor plasma samples used for pooling are from donors with a final RSV neutralization titer of at least 1800; and
B) a pharmaceutically acceptable carrier.
13. The method of claim 12 , wherein the subject has an immunodeficiency.
14. The method of claim 12 , wherein the subject has a primary immunodeficiency disease (PIDD).
15. The method of claim 12 , wherein the subject is selected from the group consisting of an end stage renal disease (ESRD) patient, a patient on immunosuppressive therapy, an AIDS patient, a diabetic patient, a neonate, a transplant patient, a patient with malfunctioning immune system, an elderly person, a patient with autoimmune disease, a burn patient, a cancer patient, and a patient in an acute care setting.
16. The method of claim 12 , wherein the immunotherapy is used to treat and/or prevent infection in the subject.
17. The method of claim 16 , wherein the infection is caused by a pathogen selected from the group consisting of respiratory syncytial virus (RSV), parainfluenza virus 1, parainfluenza virus 2, coronavirus OC43, coronavirus 229E, influenza A virus, influenza B virus, and metapneumovirus.
18. The method of claim 12 , wherein the immunotherapy is used to treat a respiratory infection in the subject.
19. The method of claim 12 , wherein the immunotherapy reduces viral load in the subject.